Investor Sorrento Therapeutics, Inc.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Sorrento Therapeutics, Inc. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2023-10-05 13G/A CELU / Celularity Inc. 20,422,124 5,050,427
2023-09-26 13D/A SCLX / Scilex Holding Company 95,533,509 1,917,210
2023-08-15 13D/A SCLX / Scilex Holding Company 95,533,509 95,533,509
2023-03-03 13D/A SCLX / Scilex Holding Company 95,533,509 95,533,509
2023-01-23 13D/A SCLX / Scilex Holding Company 167,887,687 95,533,509
2022-11-17 13D SCLX / Scilex Holding Company 167,887,687
2021-07-23 13G CELU / Celularity Inc. 20,422,124
2017-02-13 13G/A IBRX / ImmunityBio, Inc. 0 0
2017-02-11 13G/A IBRX / ImmunityBio, Inc. 5,618,326 0
2016-12-09 13G HCYT / H-CYTE Inc 937,499
2016-02-17 13G IBRX / ImmunityBio, Inc. 5,618,326